Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
600 participants
INTERVENTIONAL
2016-05-31
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Blood Loss During Cesarean Section
NCT05664659
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
NCT03680339
Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S.
NCT02277041
Misoprostol Versus Active Management of Labour in CS
NCT03390010
Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases
NCT04117243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Misoprostol + Oxytocin
400 ug sublingual misoprostol + 10 IU Oxytocin IVI
Misoprostol
Oxytocin
Placebo
Carbetocin
100 ug Carbetocin IV
Carbetocin
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Misoprostol
Oxytocin
Carbetocin
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* contraindication to prostaglandins (e.g. glaucoma)
* history of significant heart disease
* severe asthma
* epilepsy
* history or evidence of liver
* renal or vascular disease
* history of coagulopathy
* thrombocytopenia or anticoagulant therapy
* women with HELLP syndrome
* eclampsia
* women presenting by placental abruption
* contraindication to spinal anesthesia as carbetocin is licensed for use with regional anesthesia only.
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed S Sweed, MD
Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University Maternity Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AS1301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.